Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monoclonal Antibodies to Human Cell Surface Antigens.

Current protocols in immunology·2020
Same author

Peptidase inhibitor 16 identifies a human regulatory T-cell subset with reduced FOXP3 expression over the first year of recent onset type 1 diabetes.

European journal of immunology·2019
Same author

Nomenclature of CD molecules from the Tenth Human Leucocyte Differentiation Antigen Workshop.

Clinical & translational immunology·2016
Same author

CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology.

Journal of immunology (Baltimore, Md. : 1950)·2015
Same author

Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients.

Brain, behavior, and immunity·2014
Same author

Accumulation of effector memory CD8+ T cells in nasal polyps.

American journal of rhinology & allergy·2013

Related Experiment Video

Updated: Jul 7, 2026

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

1D09C3, an mAb specific for MHC-II.

Heddy Zola1, Alice Beare

  • 1Women's and Children's Health Research Institute, 72 King William Road, North Adelaide, SA 5006, South Australia. heddy.zola@adelaide.edu.au

Current Opinion in Molecular Therapeutics
|January 30, 2008
PubMed
Summary

GPC Biotech AG is developing 1D09C3, a fully human antibody targeting MHC class II (HLA-DR), for hematological malignancies. Positive safety data from initial Phase I trials were reported in December 2006.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • GPC Biotech AG is investigating 1D09C3, a fully human IgG4 antibody.
  • 1D09C3 targets MHC class II (HLA-DR) molecules.
  • MorphoSys AG developed this antibody using its HuCAL library.

Purpose of the Study:

  • To evaluate the safety and potential efficacy of 1D09C3.
  • To assess 1D09C3 as a treatment for hematological malignancies.

Main Methods:

  • Phase I clinical trials were conducted.
  • Safety data were collected and analyzed.

Main Results:

  • Positive safety data from two Phase I clinical trials were reported in December 2006.
  • Final Phase I data were anticipated in mid-2007.

More Related Videos

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin
11:17

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin
11:17

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Conclusions:

  • 1D09C3 demonstrates a positive safety profile in early clinical evaluation.
  • Further data are needed to confirm the therapeutic potential of 1D09C3 in hematological malignancies.